Olmetec

Olmesartan medoxomil

Essential HTN. 

Initially 20 mg once daily, may be increased to max: 40 mg once daily. Mild to moderate renal impairment Max: 20 mg once daily. Moderate hepatic impairment Initially 10 mg once daily, may be increased to max: 20 mg once daily.

May be taken with or without food: Take at the same time each day. Swallow whole w/ a glass of water, do not chew.

Hypersensitivity. Biliary obstruction. Concomitant use w/ aliskiren-containing products in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m²). 2nd & 3rd trimesters of pregnancy.

Not recommended in primary aldosteronism. Intravascular vol depletion, other conditions w/ renin-angiotensin-aldosterone system stimulation, renovascular HTN, hyperkalaemia, dual blockade of renin-angiotensin-aldosterone system, diabetic nephropathy, aortic/mitral valve stenosis, obstructive hypertrophic cardiomyopathy, sprue-like enteropathy, excessive decreased BP in patients w/ ischemic heart or cerebrovascular disease. Ethnic differences. Not recommended in concomitant use w/ lithium. Concomitant use w/ ACE inhibitors, K supplements, K-containing salt substitutes, K-sparing diuretics, NSAIDs including COX-2 inhibitors, heparin, ciclosporin, tacrolimus, trimethoprim. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Kidney transplantation or ESRD. Mild to moderate renal & moderate hepatic impairment. Not recommended in severe renal & hepatic impairment. Not to be initiated during 1st trimester of pregnancy. Not recommended during lactation. Childn & adolescents <18 yr. Not to be used in childn <1 yr.

Hypertriglyceridaemia, hyperuricaemia; dizziness, headache; bronchitis, pharyngitis, cough, rhinitis; gastroenteritis, diarrhoea, abdominal pain, nausea, dyspepsia; arthritis; back & skeletal pain; haematuria, UTI; pain, chest pain, peripheral oedema, flu-like symptoms, fatigue; increased hepatic enzymes, blood urea & creatine phosphokinase.

Increased BP-lowering effect by other antihypertensives. Increased risks of hypotension, hyperkalaemia & decreased renal function w/ ACE inhibitors, angiotensin II receptor blocker or aliskiren. Increased serum K levels w/ K supplements & K-sparing diuretics, K-containing salt substitutes; heparin. Synergistic effect w/ NSAIDs. Reduced systemic exposure, t_½ & peak plasma conc w/ colesevelam HCl. Reduced bioavailability by Al Mg hydroxide antacids. Increased serum lithium conc & toxicity.

Angiotensin II Antagonists

C09CA08 - olmesartan medoxomil ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

B